Company intelligence / Profile preview
Boston Immune Technologies and Therapeutics
Winchester/Boston, Massachusetts, United Statesbostonimmunetech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
BITT’s lead candidate BIR2101 targets TNFR2 and has entered Phase I clinical trials in oncology. The company has received NIH/NCI grants to support this trial. Preclinical programs include antagonist antibodies against CD40 for autoimmune/inflammatory indications and additional discovery-stage programs targeting CD30 and CD27. Early results in animal models suggest that combining TNFR2 antagonism with checkpoint inhibitors may improve cure rates in cancer models
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Antagonist antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
BeiGene Ltd. – option/license arrangement on pipeline assets; investor/board representationOtsuka/MSRD – sponsored research/exclusivity agreement on the anti-CD40 program with right to negotiate acquisition/license/collaboration related to the assetNIH/NCI – grant funding for clinical development of lead asset BIR2101/TNFR2 antagonist
Beyond the preview
Go deeper on Boston Immune Technologies and Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boston Immune Technologies and Therapeutics.